Clinical Trials Sponsored by Xu Lei

Total 5925 results

Eli Lilly and Company

Active, not recruiting

A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India

Plaque Psoriasis | Psoriatic Arthritis

India
Eli Lilly and Company

Completed

A Study of Mirikizumab (LY3074828) Injection in Healthy Participants

Healthy

United Kingdom
Eli Lilly and Company

Completed

A Study of Mirikizumab in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3074828 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India

Type 2 Diabetes Mellitus

India
Eli Lilly and Company

Completed

A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

Obesity

United States
Eli Lilly and Company

Completed

A Study of Mirikizumab (LY3074828) in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of Mirikizumab in Participants With Plaque Psoriasis

Psoriasis

United States
Eli Lilly and Company

Completed

A Study of Two Formulations of LY3074828 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) (SURMOUNT-CN)

Obesity | Overweight | Metabolism and Nutrition Disorder

China
Eli Lilly and Company

Completed

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Eli Lilly and Company

Active, not recruiting

A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer

Breast Neoplasms

China
Eli Lilly and Company

Completed

A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants

Healthy

United States
Mei Zhang

Active, not recruiting

Follow up Study of Crocin on Cardiac Function Protection in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy Based on Color Doppler Ultrasound Combined With Myocardial Zymogram

Breast Cancer

China
Eli Lilly and Company

Completed

A Study of LY3451838 in Participants With Migraine

Migraine

United States
Eli Lilly and Company

Completed

Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer (CYCLONE 1)

Metastatic Castration-Resistant Prostate Cancer

France, United States, Spain
Eli Lilly and Company

Completed

Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis

Osteoarthritis

United States, Puerto Rico
Eli Lilly and Company

No longer available

Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial

Generalized Anxiety Disorder | Fibromyalgia | Major Depressive Disorder | Diabetic Peripheral Neuropathic Pain

Australia
Eli Lilly and Company

Terminated

A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Eli Lilly and Company

Completed

A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

Healthy | Obese

United States
Eli Lilly and Company

Completed

A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors

Solid Tumor

United States, Korea, Republic of, Japan, Spain
Eli Lilly and Company

Completed

A Study of LY3337641 in Healthy Participants

Healthy

Singapore
Eli Lilly and Company

Completed

A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)

Alzheimer's Disease

United States
Eli Lilly and Company

Completed

A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease

Alzheimer Disease

United States, Japan, United Kingdom
Eli Lilly and Company

Active, not recruiting

A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD) (GERAS-US)

Alzheimer Disease | Mild Cognitive Impairment

United States
Eli Lilly and Company

Completed

A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Germany
Eli Lilly and Company

Completed

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis

Osteoarthritis | Osteo Arthritis Knee

United States, Puerto Rico
Eli Lilly and Company

Completed

A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05)

Chronic Pain | Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathy

United States, Puerto Rico
Eli Lilly and Company

Completed

A Study of LY3337641 in Japanese and Caucasian Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (RANGE)

Urothelial Carcinoma

Spain, United States, Poland, Romania, Taiwan, Ukraine, Netherlands, Mexico, Japan, France, Germany, Belgium, Greece, Russian Federation, Turkey, Canada, Israel, Italy, United Kingdom, Denmark, Korea, Republic of, Australia, Hungary
Eli Lilly and Company

Completed

A Study of LY3437943 in Chinese Participants With Obesity Or Overweight

Obesity | Overweight

China
Eli Lilly and Company

Completed

A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3437943 in Participants With Type 2 Diabetes

Type 2 Diabetes

United States, Puerto Rico
Eli Lilly and Company

Completed

A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3041658 in Adults With Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States, Australia
Eli Lilly and Company

Completed

A Study of Carbon-14-Labelled [14C] LY3372689 in Healthy Male Participants

Healthy

United States
Eli Lilly and Company

Completed

Study of Tirzepatide in Healthy Participants

Healthy

United Kingdom
Eli Lilly and Company

Completed

A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Eli Lilly and Company

Completed

A Study of LY3537021 in Healthy Participants

Healthy

Singapore
Eli Lilly and Company

Completed

A Study of Donanemab (LY3002813) in Healthy Chinese Participants

Healthy

China
Eli Lilly and Company

Completed

A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants

Healthy

United States
Eli Lilly and Company

Terminated

A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer

Advanced Solid Tumor

United States, Japan
Eli Lilly and Company

Completed

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes

Type 1 Diabetes Mellitus

China, Argentina, Mexico
Eli Lilly and Company

Terminated

Study of IMC-EB10 in Participant With Leukemia

Myeloid Leukemia

United States
Eli Lilly and Company

Completed

A Study of LY3361237 in Participants With Psoriasis

Psoriasis

Poland, Hungary, Bulgaria, Slovakia
Eli Lilly and Company

Completed

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

Healthy

United States

3

Subscribe